KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Revenue (2018 - 2025)

Historic Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $94.0 million.

  • Adaptive Biotechnologies' Revenue rose 10237.54% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.8 million, marking a year-over-year increase of 4257.17%. This contributed to the annual value of $179.0 million for FY2024, which is 509.82% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Revenue of $94.0 million as of Q3 2025, which was up 10237.54% from $58.9 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Revenue high stood at $94.0 million for Q3 2025, and its period low was $7.7 million during Q2 2023.
  • Moreover, its 5-year median value for Revenue was $43.2 million (2024), whereas its average is $44.9 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Revenue plummeted by 8236.37% in 2023 and then surged by 46090.91% in 2024.
  • Adaptive Biotechnologies' Revenue (Quarter) stood at $37.9 million in 2021, then skyrocketed by 45.53% to $55.2 million in 2022, then decreased by 17.05% to $45.8 million in 2023, then increased by 3.66% to $47.5 million in 2024, then soared by 98.01% to $94.0 million in 2025.
  • Its Revenue was $94.0 million in Q3 2025, compared to $58.9 million in Q2 2025 and $52.4 million in Q1 2025.